Trials / Completed
CompletedNCT02757352
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 303 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2016-08-02
- Primary completion
- 2019-03-01
- Completion
- 2019-05-07
- First posted
- 2016-05-02
- Last updated
- 2020-03-13
- Results posted
- 2020-03-13
Locations
109 sites across 16 countries: United States, Argentina, Austria, Brazil, Canada, Czechia, Finland, Germany, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, South Korea
Source: ClinicalTrials.gov record NCT02757352. Inclusion in this directory is not an endorsement.